Better science
better cancer detection
Easy to use, ex vivo and in vivo cancer detection that provides instantaneous, highly accurate results, without capital equipment.
NOVASCAN’S MISSION
Breakthrough Technology Improving Cancer Diagnosis
NovaScan’s leadership believes that improving the detection and stratification of cancer – be it in initial detection of cancer, during a procedure, or in post-procedural pathology – can improve patient outcomes, increase physician economics, and reduce the cost of care. We are committed to commercializing our platform technology for cancer detection and stratification, which we believe offers significant advantages over alternatives in soft tissue cancer detection. NovaScan’s first product, MarginScan Skin, offers dermatologists the opportunity for fast, predictable healthy tissue sparing skin cancer procedures.
NovaScan In the Press
NovaScan Announces a New Pancreatic Trial at the University of Illinois Medical Center
Trial will focus on chronic pancreatitis patients December 3, 2024 Chicago, IL: NovaScan, a clinical stage oncology company based in Chicago, today announced that a new clinical trial has started employing the NovaScan Canary biopsy assessment device to detect...
NovaScan Announces the Appointment of Two Luminary Advisors
Robert W. Cook, Ph.D. and Robert Zieserl will become Advisors to the company Chicago IL – October 22, 2024: NovaScan, a clinical stage oncology company based in Chicago, IL, announced the appointment of two luminary advisors who will assist the company as it advances...
Epredia and NovaScan Announce Intent for U.S. Distribution Agreement for MarginScanTM Device for Non-Melanoma Skin Cancer Detection
Avantik to Serve as Primary Distribution Partner Portsmouth, NH – May 2, 2024 – Epredia, a global leader in precision cancer diagnostics and subsidiary of PHC Holdings Corporation (TSE: 6523), and NovaScan, Inc., a company that develops breakthrough technology for...